Balyasny Asset Management
PCVX icon

Balyasny Asset Management’s Vaxcyte PCVX Stock Holding History

Balyasny Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,000
Closed -$1.63M – 3340
2025
Q2 		$1.63M Buy
50,000
+24,700
+98% +$810K ﹤0.01% 1839
2025
Q1 		$955K Buy
+25,300
New +$2.02M ﹤0.01% 2012
2023
Q3 		– Sell
-284,000
Closed -$14.2M – 2613
2023
Q2 		$14.2M Buy
+284,000
New +$13.5M 0.03% 646

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Balyasny Asset Management's PCVX Position: Q2 2026 in Review

Balyasny Asset Management sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 514,577 shares — an estimated $29.9M sold.

Balyasny Asset Management first reported a position in PCVX in Q3 2022 and held it in 7 quarters. The position peaked at $31.6M in Q2 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Balyasny Asset Management reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 514,577 Vaxcyte shares in Q2 2026, an estimated $29.9M.
  • Balyasny Asset Management first reported a position in Vaxcyte in Q3 2022 and held it in 7 quarters.
  • Balyasny Asset Management's Vaxcyte position peaked at $31.6M in Q2 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.